Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K, White RD, Udriste M, Sharma S, Dougherty B, Stetson D, Jenkins D, Mortlock A, Forcina A, Munugalavadla V, Flinn I.
Roschewski M, et al. Among authors: saba ns.
Clin Cancer Res. 2023 Sep 1;29(17):3301-3312. doi: 10.1158/1078-0432.CCR-22-2483.
Clin Cancer Res. 2023.
PMID: 37364001
Free PMC article.
Clinical Trial.